Home The Word Brain	My Amedeo FAQ Privacy About
	Amedeo C49 English + 你好 (nǐ hǎo) = limitless possibilities. Start learning Mandarin Chinese today—for free, forever. Amedeo C49 is completely free, for life. Next week: +49.

HIV Infection

Free Subscription Articles published in Lancet Infect Dis Retrieve available abstracts of 61 articles: HTML format

Single Articles

September 2025
1. HOFFMANN DAHL E, Jiba DF, Casas EC, Jonckheere S, et al
   Monkeypox virus-HIV co-infections in Sierra Leone.
   Lancet Infect Dis. 2025 Sep 12:S1473-3099(25)00542.
   PubMed    
   
   
   
2. METCALFE JZ, Weir IR, Scarsi KK, Mendoza-Ticona A, et al
   A 3-month clofazimine-rifapentine-containing regimen for drug-susceptible tuberculosis versus standard of care (Clo-Fast): a randomised, open-label, phase 2c clinical trial.
   Lancet Infect Dis. 2025 Sep 4:S1473-3099(25)00436.
   PubMed     Abstract available
   
   
   
3. TIRLANGI PK, Khan AR, Soneja M, Gupta N, et al
   Preventing vertical HIV transmission in India: the final push.
   Lancet Infect Dis. 2025 Sep 2:S1473-3099(25)00535.
   PubMed    
   
   
   August 2025
4. 
   Sotrovimab versus usual care in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial.
   Lancet Infect Dis. 2025 Aug 28:S1473-3099(25)00361.
   PubMed     Abstract available
   
   
   
5. LADHANI SN, Ramsay ME, Fifer H
   What can be learnt from the world's first national vaccination programme against gonorrhoea.
   Lancet Infect Dis. 2025 Aug 20:S1473-3099(25)00468.
   PubMed    
   
   
   July 2025
6. ANSARI R
   Memory as resistance: HIV/AIDS, care, and collective futures.
   Lancet Infect Dis. 2025 Jul 24:S1473-3099(25)00471.
   PubMed    
   
   
   
7. VAN EIJK AM, Stepniewska K, Khairallah C, Rodriguez E, et al
   The impact of sulfadoxine-pyrimethamine resistance on the effectiveness of intermittent preventive treatment for the prevention of malaria in pregnancy in Africa: an updated systematic review and meta-analysis.
   Lancet Infect Dis. 2025 Jul 14:S1473-3099(25)00219.
   PubMed     Abstract available
   
   
   
8. MINJA LT, van der Feltz I, Manyama C, Mpagama S, et al
   Delpazolid in combination with bedaquiline, delamanid, and moxifloxacin for pulmonary tuberculosis (PanACEA-DECODE-01): a prospective, randomised, open-label, phase 2b, dose-finding trial.
   Lancet Infect Dis. 2025 Jul 8:S1473-3099(25)00289.
   PubMed     Abstract available
   
   
   
9. PERUMAL R, Naidoo K
   The patient pursuit of safe treatment options for tuberculosis.
   Lancet Infect Dis. 2025 Jul 8:S1473-3099(25)00362.
   PubMed    
   
   
   
10. HEINRICH N, Manyama C, Koele SE, Mpagama S, et al
    Sutezolid in combination with bedaquiline, delamanid, and moxifloxacin for pulmonary tuberculosis (PanACEA-SUDOCU-01): a prospective, open-label, randomised, phase 2b dose-finding trial.
    Lancet Infect Dis. 2025 Jul 8:S1473-3099(25)00213.
    PubMed     Abstract available
    
    
    
11. CHALKIAS S, Dennis P, Petersen D, Radhakrishnan K, et al
    Efficacy, immunogenicity, and safety of a next-generation mRNA-1283 COVID-19 vaccine compared with the mRNA-1273 vaccine (NextCOVE): results from a phase 3, randomised, observer-blind, active-controlled trial.
    Lancet Infect Dis. 2025 Jul 7:S1473-3099(25)00236.
    PubMed     Abstract available
    
    
    June 2025
12. MDLENYANI L, Mohamed Z, Stadler JAM, Mtwa N, et al
    Treatment outcomes of bedaquiline-resistant tuberculosis: a retrospective and matched cohort study.
    Lancet Infect Dis. 2025 Jun 18:S1473-3099(25)00218.
    PubMed     Abstract available
    
    
    
13. MAERTENS JA, Thompson GR 3rd, Spec A, Donovan FM, et al
    Olorofim for the treatment of invasive fungal diseases in patients with few or no therapeutic options: a single-arm, open-label, phase 2b study.
    Lancet Infect Dis. 2025 Jun 17:S1473-3099(25)00224.
    PubMed     Abstract available
    
    
    
14. SEDDON JA, Achar J, Malik AA, Hughes J, et al
    Management of individuals exposed to multidrug-resistant or rifampicin-resistant tuberculosis.
    Lancet Infect Dis. 2025 Jun 5:S1473-3099(25)00157.
    PubMed     Abstract available
    
    
    
15. GATTI FD, Nodari JZ, Sousa TJ, Mendonca GC, et al
    Neuroinvasive Oropouche virus in a patient with HIV from extra-Amazonian Brazil.
    Lancet Infect Dis. 2025 Jun 3:S1473-3099(25)00352.
    PubMed    
    
    
    May 2025
16. PATERSON A, Mughogho KK, Cheyne A, Kabajaasi O, et al
    The (Re)-emerging And ePidemic Infectious Diseases (RAPID) Stigma Scales: a cross-outbreak scale development and pyschometric validation study.
    Lancet Infect Dis. 2025 May 30:S1473-3099(25)00161.
    PubMed     Abstract available
    
    
    
17. PATON NI, Cousins C, Sari IP, Burhan E, et al
    Efficacy and safety of 8-week regimens for the treatment of rifampicin-susceptible pulmonary tuberculosis (TRUNCATE-TB): a prespecified exploratory analysis of a multi-arm, multi-stage, open-label, randomised controlled trial.
    Lancet Infect Dis. 2025 May 22:S1473-3099(25)00151.
    PubMed     Abstract available
    
    
    
18. GRANSKOG L, Saadeh K, Lorenz K, Quint J, et al
    Effect of JYNNEOS vaccination on mpox clinical progression: a case-control study.
    Lancet Infect Dis. 2025 May 21:S1473-3099(25)00180.
    PubMed     Abstract available
    
    
    April 2025
19. VANBAELEN T, Manoharan-Basil SS, Kenyon C
    Doxy-PEP could select for ceftriaxone resistance in Neisseria gonorrhoeae.
    Lancet Infect Dis. 2025 Apr 22:S1473-3099(25)00234.
    PubMed    
    
    
    
20. LAYTON GR, Veater JB, Thombre R, Afshar B, et al
    Disseminated Mycoplasma pneumoniae infection presenting with polyarthritis and endocarditis.
    Lancet Infect Dis. 2025;25:e253-e254.
    PubMed    
    
    
    March 2025
21. SASO A, Kanteh E, Jeffries D, Okoye M, et al
    The effect of pertussis vaccination in pregnancy on the immunogenicity of acellular or whole-cell pertussis vaccination in Gambian infants (GaPS): a single-centre, randomised, controlled, double-blind, phase 4 trial.
    Lancet Infect Dis. 2025 Mar 25:S1473-3099(25)00072.
    PubMed     Abstract available
    
    
    
22. MCCLURE M, Gandhi M
    Threat of HIV and tuberculosis drug resistance after US funding cuts.
    Lancet Infect Dis. 2025 Mar 20:S1473-3099(25)00209.
    PubMed    
    
    
    
23. HILLUS D, Le NH, Tober-Lau P, Fietz AK, et al
    Safety and effectiveness of MVA-BN vaccination against mpox in at-risk individuals in Germany (SEMVAc and TEMVAc): a combined prospective and retrospective cohort study.
    Lancet Infect Dis. 2025 Mar 18:S1473-3099(25)00018.
    PubMed     Abstract available
    
    
    
24. BORGES AH, Russell M, Tait D, Scriba TJ, et al
    Immunogenicity, safety, and efficacy of the vaccine H56:IC31 in reducing the rate of tuberculosis disease recurrence in HIV-negative adults successfully treated for drug-susceptible pulmonary tuberculosis: a double-blind, randomised, placebo-controlle
    Lancet Infect Dis. 2025 Mar 5:S1473-3099(24)00814.
    PubMed     Abstract available
    
    
    February 2025
25. PROAL AD, Aleman S, Bomsel M, Brodin P, et al
    Targeting the SARS-CoV-2 reservoir in long COVID.
    Lancet Infect Dis. 2025 Feb 10:S1473-3099(24)00769.
    PubMed     Abstract available
    
    
    January 2025
26. DUNSMUIR H
    HIV and rights for queer communities in Ghana.
    Lancet Infect Dis. 2025 Jan 27:S1473-3099(25)00066.
    PubMed    
    
    
    December 2024
27. PAINTER C, Limmathurotsakul D, Roberts T, van Doorn HR, et al
    Sustainable antimicrobial resistance surveillance: time for a global funding mechanism.
    Lancet Infect Dis. 2024 Dec 17:S1473-3099(24)00649.
    PubMed     Abstract available
    
    
    
28. KIRBY T
    Justyna Kowalska-reaching underserved people with HIV.
    Lancet Infect Dis. 2024;24:1303.
    PubMed    
    
    
    November 2024
29. BAGCCHI S
    Spreading awareness about HIV transmission.
    Lancet Infect Dis. 2024 Nov 28:S1473-3099(24)00803.
    PubMed    
    
    
    
30. NAIDOO K, Perumal R
    First data of a quabodepistat containing novel regimen for drug-susceptible tuberculosis.
    Lancet Infect Dis. 2024 Nov 26:S1473-3099(24)00653.
    PubMed    
    
    
    
31. HOLT E
    Gilead under fire over HIV drug licensing.
    Lancet Infect Dis. 2024 Nov 8:S1473-3099(24)00747.
    PubMed    
    
    
    October 2024
32. DAS NEVES MARTINS FE, Chiang JO, Nunes BTD, Ribeiro BFR, et al
    Newborns with microcephaly in Brazil and potential vertical transmission of Oropouche virus: a case series.
    Lancet Infect Dis. 2024 Oct 15:S1473-3099(24)00617.
    PubMed     Abstract available
    
    
    
33. BAGCCHI S
    HIV stigma in health-care settings in Europe and central Asia.
    Lancet Infect Dis. 2024;24:e622.
    PubMed    
    
    
    
34. ORKIN C, Ring K
    Implementing long-acting injectable cabotegravir and rilpivirine in Africa.
    Lancet Infect Dis. 2024;24:1060-1061.
    PubMed    
    
    
    September 2024
35. WASSERMAN S, Donovan J, Kestelyn E, Watson JA, et al
    Advancing the chemotherapy of tuberculous meningitis: a consensus view.
    Lancet Infect Dis. 2024 Sep 26:S1473-3099(24)00512.
    PubMed     Abstract available
    
    
    
36. OLBRICH L, Franckling-Smith Z, Larsson L, Sabi I, et al
    Sequential and parallel testing for microbiological confirmation of tuberculosis disease in children in five low-income and middle-income countries: a secondary analysis of the RaPaed-TB study.
    Lancet Infect Dis. 2024 Sep 20:S1473-3099(24)00494.
    PubMed     Abstract available
    
    
    
37. PROCHAZKA M, Vinti P, Hoxha A, Seale A, et al
    Temporary adaptations to sexual behaviour during the mpox outbreak in 23 countries in Europe and the Americas: findings from a retrospective cross-sectional online survey.
    Lancet Infect Dis. 2024 Sep 18:S1473-3099(24)00531.
    PubMed     Abstract available
    
    
    
38. BAPOLISI WA, Krasemann S, Wayengera M, Kirenga B, et al
    Mpox outbreak-tecovirimat resistance, management approaches, and challenges in HIV-endemic regions.
    Lancet Infect Dis. 2024 Sep 10:S1473-3099(24)00591.
    PubMed    
    
    
    
39. HOLT E
    Setbacks and advances in the global HIV response.
    Lancet Infect Dis. 2024;24:e554.
    PubMed    
    
    
    
40. PANNIKOTTU J, Reuter A, Pietersen E, Makhanda G, et al
    Waiting is no longer an option for household contacts of people with drug-resistant tuberculosis.
    Lancet Infect Dis. 2024;24:947-949.
    PubMed    
    
    
    August 2024
41. STARBUCK E
    Biopolitical precarity for women with HIV in South Africa.
    Lancet Infect Dis. 2024 Aug 26:S1473-3099(24)00572.
    PubMed    
    
    
    
42. VANBAELEN T, Manoharan-Basil SS, Kenyon C
    Studies of post-exposure prophylaxis with doxycycline should consider population-level selection for antimicrobial resistance.
    Lancet Infect Dis. 2024 Aug 21:S1473-3099(24)00502.
    PubMed    
    
    
    
43. RACCAGNI AR, Castagna A, Nozza S
    Gonorrhoea and chlamydia screening for asymptomatic people with HIV and HIV PrEP users: open issues.
    Lancet Infect Dis. 2024 Aug 13:S1473-3099(24)00528.
    PubMed    
    
    
    July 2024
44. GRAY GE, Mngadi K, Lavreys L, Nijs S, et al
    Mosaic HIV-1 vaccine regimen in southern African women (Imbokodo/HVTN 705/HPX2008): a randomised, double-blind, placebo-controlled, phase 2b trial.
    Lancet Infect Dis. 2024 Jul 19:S1473-3099(24)00358.
    PubMed     Abstract available
    
    
    
45. LEHMANN C, Schommers P
    The need for novel approaches to HIV-1 vaccine development.
    Lancet Infect Dis. 2024 Jul 19:S1473-3099(24)00398.
    PubMed    
    
    
    June 2024
46. DECROO T, Mesic A, Decuyper I
    Longevity of modified standard short treatment regimens for rifampicin-resistant tuberculosis.
    Lancet Infect Dis. 2024 Jun 13:S1473-3099(24)00294.
    PubMed    
    
    
    
47. KOROTYCH O, Achar J, Gurbanova E, Hovhannesyan A, et al
    Effectiveness and safety of modified fully oral 9-month treatment regimens for rifampicin-resistant tuberculosis: a prospective cohort study.
    Lancet Infect Dis. 2024 Jun 13:S1473-3099(24)00228.
    PubMed     Abstract available
    
    
    
48. JOSEPH DAVEY D, de Voux A, Hlatshwayo L, Nelson A, et al
    Prevention of congenital syphilis within antenatal PrEP services in South Africa: missed opportunities.
    Lancet Infect Dis. 2024;24:571-572.
    PubMed    
    
    
    May 2024
49. KITYO C, Mambule IK, Musaazi J, Sokhela S, et al
    Switch to long-acting cabotegravir and rilpivirine in virologically suppressed adults with HIV in Africa (CARES): week 48 results from a randomised, multicentre, open-label, non-inferiority trial.
    Lancet Infect Dis. 2024 May 28:S1473-3099(24)00289.
    PubMed     Abstract available
    
    
    
50. MOLINA JM, Bercot B, Assoumou L, Rubenstein E, et al
    Doxycycline prophylaxis and meningococcal group B vaccine to prevent bacterial sexually transmitted infections in France (ANRS 174 DOXYVAC): a multicentre, open-label, randomised trial with a 2 x 2 factorial design.
    Lancet Infect Dis. 2024 May 23:S1473-3099(24)00236.
    PubMed     Abstract available
    
    
    
51. CEVIK M, Thompson LC, Upton C, Rolla VC, et al
    Bedaquiline-pretomanid-moxifloxacin-pyrazinamide for drug-sensitive and drug-resistant pulmonary tuberculosis treatment: a phase 2c, open-label, multicentre, partially randomised controlled trial.
    Lancet Infect Dis. 2024 May 17:S1473-3099(24)00223.
    PubMed     Abstract available
    
    
    April 2024
52. JIN SL, Kolis J, Parker J, Proctor DA, et al
    Social histories of public health misinformation and infodemics: case studies of four pandemics.
    Lancet Infect Dis. 2024 Apr 19:S1473-3099(24)00105.
    PubMed     Abstract available
    
    
    
53. 
    Global burden associated with 85 pathogens in 2019: a systematic analysis for the Global Burden of Disease Study 2019.
    Lancet Infect Dis. 2024 Apr 16:S1473-3099(24)00158.
    PubMed     Abstract available
    
    
    
54. PELUSO MJ, Swank ZN, Goldberg SA, Lu S, et al
    Plasma-based antigen persistence in the post-acute phase of COVID-19.
    Lancet Infect Dis. 2024 Apr 8:S1473-3099(24)00211.
    PubMed    
    
    
    March 2024
55. CHAKAYA J, Fatma R, Cader M, Harries AD, et al
    Post-tuberculosis lung disease: is there a light at the end of tunnel?
    Lancet Infect Dis. 2024 Mar 22:S1473-3099(24)00136.
    PubMed    
    
    
    
56. NAIDOO K, Perumal R, Cox H, Mathema B, et al
    The epidemiology, transmission, diagnosis, and management of drug-resistant tuberculosis-lessons from the South African experience.
    Lancet Infect Dis. 2024 Mar 22:S1473-3099(24)00144.
    PubMed     Abstract available
    
    
    
57. LADHANI SN, White PJ, Campbell H, Mandal S, et al
    Use of a meningococcal group B vaccine (4CMenB) in populations at high risk of gonorrhoea in the UK.
    Lancet Infect Dis. 2024 Mar 20:S1473-3099(24)00031.
    PubMed     Abstract available
    
    
    
58. 
    Global, regional, and national age-specific progress towards the 2020 milestones of the WHO End TB Strategy: a systematic analysis for the Global Burden of Disease Study 2021.
    Lancet Infect Dis. 2024 Mar 19:S1473-3099(24)00007.
    PubMed     Abstract available
    
    
    
59. STUCK L, Klinkenberg E, Abdelgadir Ali N, Basheir Abukaraig EA, et al
    Prevalence of subclinical pulmonary tuberculosis in adults in community settings: an individual participant data meta-analysis.
    Lancet Infect Dis. 2024 Mar 12:S1473-3099(24)00011.
    PubMed     Abstract available
    
    
    
60. COHN J, Mendelson M, Kanj SS, Shafiq N, et al
    Accelerating antibiotic access and stewardship: a new model to safeguard public health.
    Lancet Infect Dis. 2024 Mar 11:S1473-3099(24)00070.
    PubMed     Abstract available
    
    
    
61. DAS M
    UNICEF report reveals gender gaps persist in HIV.
    Lancet Infect Dis. 2024;24:e159.
    PubMed    
    
    

Thank you for your interest in scientific medicine.

AMEDEO HIV Infection is free of charge.